Augmented Reality: Patient Experience Trumps Misconceptions Around Injectables
19.4.2023 08:00:00 EEST | Business Wire | Press release
New global research,2 sponsored by Galderma and released today by leading filler brand Restylane®, has revealed the prevalent societal misconceptions and stereotypes facing the aesthetics industry. Forty percent of respondents admitted they would discourage others from using facial injectables to reduce wrinkles or provide volume. A further 34% said they believed the results of such treatments look fake and unnatural.
Despite holding these views, when the same respondents were presented with a range of images of people who had undergone filler treatments, the data told another story. On average, 4 out of 5 people could not always identify those who had received filler.3 This highlights the common misconceptions about these types of treatments and the results they deliver.
The perceptions surrounding the use of temporary fillers stand in stark contrast to those around the use of permanent beauty treatments such as tattoos, body piercings and dental corrections. Tattoos and body piercings are primarily seen as a positive form of self-expression (30% of respondents agreed for tattoos, and 24% for body piercings). Teeth straightening is viewed by 47% of respondents as a great way to enhance your appearance. Meanwhile, over a third of respondents (35%) believe fillers create unrealistic beauty standards and ideals, while 26% feel they can easily become addictive and 24% say they are an extreme option.
However, Restylane patient feedback data shows that 96% of people who used fillers felt their treatment exceeded expectations,4 and 95% of patients had maintained or enhanced the naturalness of their facial expressions after treatment.5,6
|
“This new research by Restylane highlights the perception that people are choosing procedures such as fillers because they lack confidence or are going to extremes to get their desired look. But this just isn’t the case! The vast majority of the clients I see are opting for small, subtle changes that will help them create their own look and feel empowered to be the best version of themselves. In my opinion, these people are inherently self-confident, know their own minds and are simply taking control of their own looks.”
DR. LUIZ AVELAR PLASTIC SURGEON BELO HORIZONTE, BRAZIL
|
The prevalence of societal judgements and the impact they have on how people behave are laid bare in the study. Only 11% of respondents said they would be supportive if a friend or family member told them they were considering using fillers. In contrast, according to Restylane patient feedback, 99% of those who have received treatment would recommend Restylane to a friend.4,6
Media leads in debunking misconceptions
The results also reveal that people see the media as more progressive in its views about aesthetic treatments. 27% percent of respondents said the media portrays injectables as empowering, while just 13% would personally describe them this way. Adult Gen Z7 respondents displayed a more open-minded attitude toward aesthetic procedures and were more likely to see treatments of this nature as empowering (19% in this age group agreed versus 13% overall). They were almost three times more likely to feel positively toward fillers than those over 55 years old, only 7% of whom agreed. Younger consumers also feel that people seeking injectable treatments are inherently more confident.
|
“I’m finding the newer generation is even more open-minded and interested when it comes to injectables. They consider aesthetic treatments to further define and enhance how they look and feel. Given that Restylane studies show that those who use dermal fillers feel overwhelmingly positive about their treatment, we are likely to see more people using them as a means of empowerment.”
STEVEN DAYAN, M.D. FACIAL PLASTIC SURGEON, PROFESSOR AND DIRECTOR OF DENOVA RESEARCH CHICAGO, ILLNOIS, U.S.
|
The research appears ahead of a Restylane product placement spot in new action-comedy film Mafia Mamma, directed by Catherine Hardwicke of Twilight fame and co-starring Toni Collette and Monica Bellucci. Mafia Mamma celebrates female empowerment and sees Toni Collette’s character challenging her comically clueless colleagues and their outdated attitudes about the reasons why women chose to undergo aesthetic treatments. While the film uses humor to highlight these stereotypes and the judgements people make about injectables, the attitudinal study highlights how these real-life judgements are still prevalent in society. Such beliefs have a tangible impact on the way people behave toward those considering fillers.
|
“We believe in championing everybody’s right to pursue their own beauty ideals. Our research findings are shining a spotlight on some of the misconceptions people have about aesthetic treatments. In this way, we hope to better equip people to make the decision that is right for them, without worrying about external pressures and judgements.”
GERRY MUHLE HEAD OF GLOBAL BUSINESS UNIT, AESTHETICS GALDERMA
|
About Restylane®
Restylane is the original non-animal stabilized hyaluronic acid filler with over 26 years of achievement and over 55 million treatments worldwide. NASHA™ and OBT™ technologies make Restylane the world’s most diverse range of fillers to deliver truly individualized results.4,5
The Restylane portfolio of products includes Restylane, Restylane Lyft™, Restylane Kysse™, Restylane Volyme™, Restylane® Defyne™, Restylane® Refyne™, Restylane® EYELIGHT™, Restylane SKINBOOSTERS™ VITAL and Restylane SKINBOOSTERS™ VITAL LIGHT.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information, visit: www.galderma.com.
Footnotes
1 Injectables are aesthetic products which are injected under the skin for a variety of reasons. These include relaxing muscles to alleviate facial wrinkles and folds, or helping contour areas of the face or body, e.g., by restoring volume or adding projection. They often come in the form of products such as botulinum toxin or HA-fillers.
2 Research was carried out by YouGov surveying 9,733 people across the UK, U.S., Canada, Brazil, Germany and Thailand between January 17 and 27, 2023.
3 Respondents were shown six images of people who had used dermal fillers and were asked to indicate if they think the person in the image had used dermal fillers.
4 Andriopoulos B, et al. Presented at: AMWC Monte Carlo, Monaco. 2019.
5 Phillipp-Dormston W, et al. J Cosmet Dermatol. 2020;19:1600–6.
6 Hilton S, et al. Dermatol Surg. 2018;44:261–9.6
7 Adult Gen Z includes those in the 18-24 age bracket.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418006014/en/
Contact information
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
Sebastien.cros@galderma.com
+41 79 529 59 85
Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 17:04:00 EEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 16:21:00 EEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
Meta Signs Agreement With AWS to Power Agentic AI on AWS Graviton Chips24.4.2026 15:10:00 EEST | Press release
Meta has signed an agreement to deploy AWS Graviton processors at scale. The deal marks a significant expansion of a long-standing partnership between the two companies as Meta builds its next generation of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424641117/en/ The deployment starts with tens of millions of Graviton cores, with the flexibility to expand as Meta's AI capabilities grow. The deal reflects a shift in how AI infrastructure gets built: while GPUs remain essential for training large models, the rise of agentic AI is creating massive demand for CPU-intensive workloads—real-time reasoning, code generation, search, and orchestrating multi-step tasks. Graviton5 is purpose-built for these workloads, giving Meta the processing power to run them efficiently at scale. The chips will power various workloads at Meta, including supporting the company’s AI efforts. That work requires infrastructure that can handle
Meta Signs Agreement With AWS to Power Agentic AI on AWS Graviton Chips24.4.2026 15:10:00 EEST | Press release
Meta has signed an agreement to deploy AWS Graviton processors at scale. The deal marks a significant expansion of a long-standing partnership between the two companies as Meta builds its next generation of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424641117/en/ The deployment starts with tens of millions of Graviton cores, with the flexibility to expand as Meta's AI capabilities grow. The deal reflects a shift in how AI infrastructure gets built: while GPUs remain essential for training large models, the rise of agentic AI is creating massive demand for CPU-intensive workloads—real-time reasoning, code generation, search, and orchestrating multi-step tasks. Graviton5 is purpose-built for these workloads, giving Meta the processing power to run them efficiently at scale. The chips will power various workloads at Meta, including supporting the company’s AI efforts. That work requires infrastructure that can handle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
